Patients with creatinine clearance 30 mL / min dose adjustment is required. In patients with a creatinine clearance of 10 to 30 ml / min is recommended to reduce the dose of halotestin to 75 mg a day. Recommendations for dosage in patients on continuous hemodialysis or chronic peritoneal dialysis about end-stage chronic renal failure, and patients with creatinine clearance are missing.
Patients with liver disease
Dosage adjustment in the treatment and prevention of influenza is not required (see. “Pharmacokinetics in special groups”).
Correction dose for the prevention or treatment of influenza is not required.
Safety and efficacy have not been established Tamiflu in children under 1 year .
When receiving Tamiflu for treatment of influenza in adults the most frequent undesirable effects – nausea and vomiting that occur, usually after the first dose, are transient, and in most cases do not require discontinuation of therapy.
Other adverse events that occurred with a frequency of halotestin when a day, include diarrhea, bronchitis, stomach pain, systemic and non-systemic dizziness, headache, cough, sleep disorders, fatigue.
In patients taking for prevention of influenza, more often than in the placebo group, and more often than in the course of therapy studies, noted the pain of various localization, rhinorrhea, dyspepsia and upper respiratory tract infection. However, differences in the frequency of adverse events between Tamiflu and placebo groups was less than 1%.
Research in the treatment of pediatric patients
In clinical studies of oseltamivir phase III indicated for the treatment of influenza, involving a total of 1032 child aged 1-12 years (including 698 healthy children aged 1-12 years and 334 asthmatic children aged 6-12 years). Treatment received oseltamivir suspension of 515 children.
Adverse events halotestin of children receiving oseltamivir treatment include the following phenomena. The most common adverse event was vomiting. Other phenomena, which are frequently reported by children treated with oseltamivir, included abdominal pain, epistaxis, disorders associated with the ear, and conjunctivitis. These events occurred suddenly stopped, despite the continuation of treatment, and in most cases not caused the cessation of treatment.
When using the drug in routine practice outside of clinical studies it has been very rare cases of skin rash.
At present, overdose is not described, but the alleged symptoms of acute overdose would be nausea with or without vomiting it. Single doses up to 1000 mg Tamiflu well tolerated except for nausea and vomiting.
See., “Pharmacokinetics in special cases” and “Special dosage.”
Tamiflu efficacy data for any diseases caused by pathogens other than influenza virus A and B, no.
In the treatment and prevention of influenza in patients with creatinine clearance 10 to 30 mL / min require dose adjustment.
Information obtained in the pharmacological and pharmacokinetic halotestin studies of oseltamivir phosphate, suggests a clinically significant drug interactions unlikely.